NBTK.DE vs. ARKG
Compare and contrast key facts about Invesco Nasdaq Biotech UCITS ETF (NBTK.DE) and ARK Genomic Revolution Multi-Sector ETF (ARKG).
NBTK.DE and ARKG are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. NBTK.DE is a passively managed fund by Invesco that tracks the performance of the Nasdaq Biotechnology. It was launched on Nov 6, 2014. ARKG is an actively managed fund by ARK Investment Management. It was launched on Oct 31, 2014.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: NBTK.DE or ARKG.
Correlation
The correlation between NBTK.DE and ARKG is 0.55, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
NBTK.DE vs. ARKG - Performance Comparison
Key characteristics
NBTK.DE:
0.32
ARKG:
-0.32
NBTK.DE:
0.55
ARKG:
-0.21
NBTK.DE:
1.07
ARKG:
0.98
NBTK.DE:
0.32
ARKG:
-0.16
NBTK.DE:
1.10
ARKG:
-0.58
NBTK.DE:
5.11%
ARKG:
22.44%
NBTK.DE:
17.67%
ARKG:
40.09%
NBTK.DE:
-30.99%
ARKG:
-80.10%
NBTK.DE:
-7.93%
ARKG:
-75.25%
Returns By Period
In the year-to-date period, NBTK.DE achieves a 2.58% return, which is significantly lower than ARKG's 17.48% return.
NBTK.DE
2.58%
2.08%
-1.40%
5.68%
4.03%
N/A
ARKG
17.48%
17.15%
7.17%
-10.49%
-5.33%
2.75%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
NBTK.DE vs. ARKG - Expense Ratio Comparison
NBTK.DE has a 0.40% expense ratio, which is lower than ARKG's 0.75% expense ratio.
Risk-Adjusted Performance
NBTK.DE vs. ARKG — Risk-Adjusted Performance Rank
NBTK.DE
ARKG
NBTK.DE vs. ARKG - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Invesco Nasdaq Biotech UCITS ETF (NBTK.DE) and ARK Genomic Revolution Multi-Sector ETF (ARKG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
NBTK.DE vs. ARKG - Dividend Comparison
Neither NBTK.DE nor ARKG has paid dividends to shareholders.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
NBTK.DE Invesco Nasdaq Biotech UCITS ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
ARKG ARK Genomic Revolution Multi-Sector ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.62% | 0.85% | 3.14% | 1.94% | 1.34% |
Drawdowns
NBTK.DE vs. ARKG - Drawdown Comparison
The maximum NBTK.DE drawdown since its inception was -30.99%, smaller than the maximum ARKG drawdown of -80.10%. Use the drawdown chart below to compare losses from any high point for NBTK.DE and ARKG. For additional features, visit the drawdowns tool.
Volatility
NBTK.DE vs. ARKG - Volatility Comparison
The current volatility for Invesco Nasdaq Biotech UCITS ETF (NBTK.DE) is 5.65%, while ARK Genomic Revolution Multi-Sector ETF (ARKG) has a volatility of 12.62%. This indicates that NBTK.DE experiences smaller price fluctuations and is considered to be less risky than ARKG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.